Genomic Testing Cooperative (GTC) is a different kind of cancer diagnostic laboratory. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. In creating a network of Co-Op partners, we help get results to physicians faster, share knowledge and generate better outcomes for patients.
Our testing is focused on comprehensive profiling of DNA and RNA in hematologic neoplasms and solid tumors, embracing the latest sequencing technology and informatics tools; providing better insights into the patient’s tumor signature. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression and prediction. Our RNA profiling can be used to compliment flow cytometry and immunohistochemistry (IHC) testing. GTC’s capabilities include liquid biopsy testing that give physicians testing options when tissue or bone marrow isn’t available. The informatics tools we use utilize artificial intelligence with sophisticated algorithms to interpret complex data sets, these informatics tools are unmatched anywhere on the market today.
GTC was founded in 2018 by Maher Albitar, MD who has held senior roles at numerous diagnostic laboratories and was a tenured professor at MD Anderson Cancer Center. He has committed his life to helping cancer patients by advancing cancer diagnostics and democratizing testing. Dr. Albitar founded GTC because he had a vision to revolutionize diagnostics and scientific discovery by improving access to comprehensive genomic profiling with next generation sequencing. He believes every cancer patient should have access to comprehensive genomic profiling. Dr. Albitar is regularly published in the top medical journals in oncology and has over 300 publications and authored over 50 patents.
We offer advanced genomic profiling for both solid and hematologic cancers to communities everywhere at an affordable price.
We utilize a cooperative business model to help physicians treat patients locally with the most advanced precision medicine.
We embrace disruptive deep learning and advanced technology to create scalable efficiencies, incomparable precision, and a more personalized approach to patient care.
We are committed to driving the field of oncology forward by enabling more patients to contribute their unique cancer experience to the growing body of cancer genomics data.
We are committed to fulfilling precision medicine’s promise of individualized care for everyone by empowering physicians to formulate treatments that best suit each patient’s unique genetic profile.
Machine / Deep Learning (AI) is the center of our analysis
